{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:20:49Z","timestamp":1792448449473,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81673340"],"award-info":[{"award-number":["81673340"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973224"],"award-info":[{"award-number":["81973224"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jconrel.2024.09.020","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T20:29:53Z","timestamp":1726864193000},"page":"513-523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["LNP-mRNA vaccine prevents type 1 diabetes in non-obese diabetes mice"],"prefix":"10.1016","volume":"375","author":[{"given":"Jiayin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zichuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianglong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigui","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.09.020_bb0005","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.09.020_bb0010","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa2308743","article-title":"Teplizumab and \u03b2-cell function in newly diagnosed type 1 diabetes","volume":"389","author":"Ramos","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.09.020_bb0015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1126\/scitranslmed.abc8980","article-title":"Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals","volume":"13","author":"Sims","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2024.09.020_bb0020","doi-asserted-by":"crossref","first-page":"730414","DOI":"10.3389\/fimmu.2021.730414","article-title":"Overcoming obstacles in the development of antigen-specific immunotherapies for type 1 diabetes","volume":"12","author":"Thomas","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.09.020_bb0025","first-page":"9","article-title":"Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes","volume":"9","author":"Ali","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2024.09.020_bb0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fimmu.2020.564921","article-title":"Glutamic acid decarboxylase injection into lymph nodes: beta cell function and immune responses in recent onset type 1 diabetes patients","volume":"11","author":"Casas","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.09.020_bb0035","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1210\/clinem\/dgac343","article-title":"Intralymphatic GAD-alum (Diamyd\u00ae) improves glycemic control in type 1 diabetes with HLA DR3-DQ2","volume":"107","author":"Nowak","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jconrel.2024.09.020_bb0040","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2024.09.020_bb0045","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.1021\/acsnano.2c12420","article-title":"Use of a liver-targeting immune-tolerogenic mRNA lipid nanoparticle platform to treat peanut-induced anaphylaxis by single- and multiple-epitope nucleotide sequence delivery","volume":"17","author":"Xu","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2024.09.020_bb0050","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41587-019-0015-4","article-title":"Antigen-specific therapeutic approaches for autoimmunity","volume":"37","author":"Serra","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2024.09.020_bb0055","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12943-023-01807-w","article-title":"The use of RNA-based treatments in the field of cancer immunotherapy","volume":"22","author":"Chehelgerdi","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2024.09.020_bb0060","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jconrel.2019.08.002","article-title":"Development of a lipoplex-type mRNA carrier composed of an ionizable lipid with a vitamin E scaffold and the KALA peptide for use as an ex vivo dendritic cell-based cancer vaccine","volume":"310","author":"Tateshita","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.09.020_bb0065","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1126\/science.aay3638","article-title":"A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis","volume":"371","author":"Krienke","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2024.09.020_bb0070","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2024.09.020_bb0075","series-title":"US Prescribing Information: ONPATTRO (Patisiran) Lipid Complex Injection, for Intravenous Use","author":"Inc","year":"2018"},{"key":"10.1016\/j.jconrel.2024.09.020_bb0080","article-title":"Comparison of DLin-MC3-DMA and ALC-0315 for siRNA delivery to hepatocytes and hepatic stellate cells","volume":"8","author":"Ferraresso","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2024.09.020_bb0085","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2217\/nnm-2020-0477","article-title":"A novel gene therapy for neurodegenerative Lafora disease via EPM2A-loaded DLinDMA lipoplexes","volume":"16","author":"Vemana","year":"2021","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2024.09.020_bb0090","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics--developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2024.09.020_bb0095","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41586-021-03738-2","article-title":"SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses","volume":"596","author":"Turner","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2024.09.020_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12010059","article-title":"Biodistribution of RNA vaccines and of their products: evidence from human and animal studies","volume":"12","author":"Pateev","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.jconrel.2024.09.020_bb0105","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.omtm.2023.05.008","article-title":"Studying how administration route and dose regulates antibody generation against LNPs for mRNA delivery with single-particle resolution, molecular therapy","volume":"29","author":"M\u00fcnter","year":"2023","journal-title":"Methods Clin. Develop."},{"key":"10.1016\/j.jconrel.2024.09.020_bb0110","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","article-title":"Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes","volume":"217","author":"Pardi","year":"2015","journal-title":"J. Controll. Release"},{"key":"10.1016\/j.jconrel.2024.09.020_bb0115","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.4161\/hv.28371","article-title":"Cholera toxin B subunit acts as a potent systemic adjuvant for HIV-1 DNA vaccination intramuscularly in mice","volume":"10","author":"Hou","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.jconrel.2024.09.020_bb0120","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3390\/vaccines3030579","article-title":"Cholera toxin subunit B as adjuvant--an accelerator in protective immunity and a break in autoimmunity","volume":"3","author":"Stratmann","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jconrel.2024.09.020_bb0125","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3109\/08820130903124770","article-title":"Immunotherapy of autoimmune diabetes by nasal administration of tandem glutamic acid decarboxylase 65 peptides","volume":"38","author":"Wang","year":"2009","journal-title":"Immunol. Investig."},{"key":"10.1016\/j.jconrel.2024.09.020_bb0130","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fimmu.2022.836274","article-title":"R848 adjuvant laden with self-assembled nanoparticle-based mRNA vaccine elicits protective immunity against H5N1 in mice","volume":"13","author":"Zhuang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.09.020_bb0135","first-page":"15","article-title":"Development of an mRNA-LNP vaccine against SARS-CoV-2: evaluation of immune response in mouse and rhesus macaque","volume":"9","author":"Sohi","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.jconrel.2024.09.020_bb0140","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.cmet.2018.09.011","article-title":"Lymphocyte-derived exosomal MicroRNAs promote pancreatic \u03b2 cell death and may contribute to type 1 diabetes development","volume":"29","author":"Guay","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.jconrel.2024.09.020_bb0145","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s00125-017-4492-z","article-title":"A Coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of type 1 diabetes","volume":"61","author":"Stone","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.jconrel.2024.09.020_bb0150","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fendo.2022.883000","article-title":"Preclinical models to evaluate the human response to autoantigen and antigen-specific immunotherapy in human type 1 diabetes","volume":"13","author":"Houeiss","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.jconrel.2024.09.020_bb0155","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.immuni.2010.04.001","article-title":"Etiology of type 1 diabetes","volume":"32","author":"Todd","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2024.09.020_bb0160","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa0804328","article-title":"GAD treatment and insulin secretion in recent-onset type 1 diabetes","volume":"359","author":"Ludvigsson","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.09.020_bb0165","series-title":"Intralymphatic Glutamic Acid Decarboxylase With Vitamin D Supplementation in Recent-Onset Type 1 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial, Diabetes Care","first-page":"1604","volume":"44","author":"Ludvigsson","year":"2021"},{"key":"10.1016\/j.jconrel.2024.09.020_bb0170","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(05)60474-6","article-title":"A cyclophosphamide-induced autoimmune diabetes","volume":"352","author":"Atlan-Gepner","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2024.09.020_bb0175","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/BF00276978","article-title":"Promotion of spontaneous diabetes in non-obese diabetes-prone mice by cyclophosphamide","volume":"27","author":"Harada","year":"1984","journal-title":"Diabetologia"},{"key":"10.1016\/j.jconrel.2024.09.020_bb0180","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/pharmaceutics15092182","article-title":"Recent advances and innovations in the preparation and purification of in vitro-transcribed-mRNA-based molecules","volume":"15","author":"Zhang","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2024.09.020_bb0185","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","article-title":"A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA","volume":"15","author":"Baiersd\u00f6rfer","year":"2019","journal-title":"Mol. Ther. Nucl. Acids"},{"key":"10.1016\/j.jconrel.2024.09.020_bb0190","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA","volume":"39","author":"Karik\u00f3","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2024.09.020_bb0195","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1093\/nar\/gky177","article-title":"An origin of the immunogenicity of in vitro transcribed RNA","volume":"46","author":"Mu","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2024.09.020_bb0200","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Therapy"},{"key":"10.1016\/j.jconrel.2024.09.020_bb0205","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202303261","article-title":"Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy","volume":"35","author":"Zong","year":"2023","journal-title":"Adv. Mater. (Deerfield Beach, Fla.)"},{"key":"10.1016\/j.jconrel.2024.09.020_bb0210","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJMra1911109","article-title":"Tolerance in the age of immunotherapy","volume":"383","author":"Bluestone","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.09.020_bb0215","series-title":"Annual Review of Immunology","first-page":"531","article-title":"Regulatory T cells: Mechanisms of differentiation and function","volume":"vol. 30","author":"Josefowicz","year":"2012"},{"key":"10.1016\/j.jconrel.2024.09.020_bb0220","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41590-020-0766-6","article-title":"Circulating T cells as a marker for early therapeutic intervention in T1D","volume":"21","author":"Bettelli","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2024.09.020_bb0225","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/cei.12672","article-title":"CD4 T cell differentiation in type 1 diabetes","volume":"183","author":"Walker","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jconrel.2024.09.020_bb0230","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/jcmm.12270","article-title":"Advances in the cellular immunological pathogenesis of type 1 diabetes","volume":"18","author":"Li","year":"2014","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.jconrel.2024.09.020_bb0235","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/pharmaceutics14091782","article-title":"Cutting-edge delivery systems and adjuvants in tolerogenic vaccines: a review","volume":"14","author":"Puricelli","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2024.09.020_bb0240","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2337\/dbi18-0066","article-title":"The evolving landscape of autoantigen discovery and characterization in type 1 diabetes","volume":"68","author":"Purcell","year":"2019","journal-title":"Diabetes"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924006308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924006308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:44:42Z","timestamp":1777509882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924006308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":48,"alternative-id":["S0168365924006308"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.09.020","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LNP-mRNA vaccine prevents type 1 diabetes in non-obese diabetes mice","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}